Used in the treatment of Parkinson’s disease, this antibody targets misfolded alpha-synuclein proteins in the brain. It helps slow down disease progression by clearing pathological protein aggregates associated with neurodegeneration. Administered intravenously, it is part of immunotherapy approaches aimed at modifying the underlying biology of Parkinson’s rather than just managing symptoms. Clinical studies focus on its ability to preserve motor function and delay disability.